AyuVis receives FDA Fast Track for drug preventing preterm infant lung disease
October 15, 2024 • CBTS, faculty, P&N, Research
Congrats to Dr. Suchismita Acharya, founder and CEO of AyuVis and assistant professor of Pharmacology and Neuroscience at CBTS.
AyuVis Research Inc., a clinical-stage biopharmaceutical company incubated at The University of North Texas Health Science Center at Fort Worth’s HSC Next Innovation Labs, recently announced that the U.S. Food and Drug Administration granted Fast Track designation to its investigational drug, AVR-48.
This designation is for AVR-48’s potential use in the prevention of bronchopulmonary dysplasia, a leading cause of mortality and long-term complications in preterm infants.
“This recognition is a significant milestone in our journey to develop groundbreaking immunotherapies aimed at preventing BPD,” said Acharya. “It underscores our dedication to addressing unmet medical needs and brings us closer to offering this critical solution to pediatric patients.”
Social media